Literature DB >> 34373989

Quantitative CT texture analysis in predicting PD-L1 expression in locally advanced or metastatic NSCLC patients.

Stefano Bracci1, Miriam Dolciami1, Claudio Trobiani1, Antonella Izzo1, Angelina Pernazza1, Giulia D'Amati1, Lucia Manganaro1, Paolo Ricci2.   

Abstract

PURPOSE: The assessment of Programmed death-ligand 1 (PD-L1) expression has become a game changer in the treatment of patients with advanced non-small cell lung cancer (NSCLC). We aimed to investigate the ability of Radiomics applied to computed tomography (CT) in predicting PD-L1 expression in patients with advanced NSCLC.
METHODS: By applying texture analysis, we retrospectively analyzed 72 patients with advanced NSCLC. The datasets were randomly split into a training cohort (2/3) and a validation cohort (1/3). Forty radiomic features were extracted by manually drawing tumor volumes of interest (VOIs) on baseline contrast-enhanced CT. After selecting features on the training cohort, two predictive models were created using binary logistic regression, one for PD-L1 values ≥ 50% and the other for values between 1 and 49%. The two models were analyzed with ROC curves and tested in the validation cohort.
RESULTS: The Radiomic Score (Rad-Score) for PD-L1 values ≥ 50%, which consisted of Skewness and Low Gray-Level Zone Emphasis (GLZLM_LGZE), presented a cut-off value of - 0.745 with an area under the curve (AUC) of 0.811 and 0.789 in the training and validation cohort, respectively. The Rad-Score for PD-L1 values between 1 and 49% consisted of Sphericity, Skewness, Conv_Q3 and Gray Level Non-Uniformity (GLZLM_GLNU), showing a cut-off value of 0.111 with AUC of 0.763 and 0.806 in the two population, respectively.
CONCLUSION: Rad-Scores obtained from CT texture analysis could be useful for predicting PD-L1 expression and guiding the therapeutic choice in patients with advanced NSCLC.
© 2021. The Author(s).

Entities:  

Keywords:  Chest CT; Lung cancer; PD-L1 expression; Texture analysis

Year:  2021        PMID: 34373989     DOI: 10.1007/s11547-021-01399-9

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  26 in total

1.  Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non--Small-Cell Lung Cancer.

Authors:  Satoru Kitazono; Yutaka Fujiwara; Koji Tsuta; Hirofumi Utsumi; Shintaro Kanda; Hidehito Horinouchi; Hiroshi Nokihara; Noboru Yamamoto; Shinji Sasada; Shun-ichi Watanabe; Hisao Asamura; Tomohide Tamura; Yuichiro Ohe
Journal:  Clin Lung Cancer       Date:  2015-04-04       Impact factor: 4.785

2.  Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

Authors:  Leena Gandhi; Delvys Rodríguez-Abreu; Shirish Gadgeel; Emilio Esteban; Enriqueta Felip; Flávia De Angelis; Manuel Domine; Philip Clingan; Maximilian J Hochmair; Steven F Powell; Susanna Y-S Cheng; Helge G Bischoff; Nir Peled; Francesco Grossi; Ross R Jennens; Martin Reck; Rina Hui; Edward B Garon; Michael Boyer; Belén Rubio-Viqueira; Silvia Novello; Takayasu Kurata; Jhanelle E Gray; John Vida; Ziwen Wei; Jing Yang; Harry Raftopoulos; M Catherine Pietanza; Marina C Garassino
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

3.  Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies.

Authors:  M Ilie; E Long-Mira; C Bence; C Butori; S Lassalle; L Bouhlel; L Fazzalari; K Zahaf; S Lalvée; K Washetine; J Mouroux; N Vénissac; M Poudenx; J Otto; J C Sabourin; C H Marquette; V Hofman; P Hofman
Journal:  Ann Oncol       Date:  2015-10-19       Impact factor: 32.976

Review 4.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

5.  Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

Authors:  Corey J Langer; Shirish M Gadgeel; Hossein Borghaei; Vassiliki A Papadimitrakopoulou; Amita Patnaik; Steven F Powell; Ryan D Gentzler; Renato G Martins; James P Stevenson; Shadia I Jalal; Amit Panwalkar; James Chih-Hsin Yang; Matthew Gubens; Lecia V Sequist; Mark M Awad; Joseph Fiore; Yang Ge; Harry Raftopoulos; Leena Gandhi
Journal:  Lancet Oncol       Date:  2016-10-10       Impact factor: 41.316

6.  Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.

Authors:  Luis Paz-Ares; Alexander Luft; David Vicente; Ali Tafreshi; Mahmut Gümüş; Julien Mazières; Barbara Hermes; Filiz Çay Şenler; Tibor Csőszi; Andrea Fülöp; Jerónimo Rodríguez-Cid; Jonathan Wilson; Shunichi Sugawara; Terufumi Kato; Ki Hyeong Lee; Ying Cheng; Silvia Novello; Balazs Halmos; Xiaodong Li; Gregory M Lubiniecki; Bilal Piperdi; Dariusz M Kowalski
Journal:  N Engl J Med       Date:  2018-09-25       Impact factor: 91.245

7.  Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.

Authors:  Tony S K Mok; Yi-Long Wu; Iveta Kudaba; Dariusz M Kowalski; Byoung Chul Cho; Hande Z Turna; Gilberto Castro; Vichien Srimuninnimit; Konstantin K Laktionov; Igor Bondarenko; Kaoru Kubota; Gregory M Lubiniecki; Jin Zhang; Debra Kush; Gilberto Lopes
Journal:  Lancet       Date:  2019-04-04       Impact factor: 79.321

8.  Quantifying tumour heterogeneity with CT.

Authors:  Balaji Ganeshan; Kenneth A Miles
Journal:  Cancer Imaging       Date:  2013-03-26       Impact factor: 3.909

9.  The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).

Authors:  Julie R Brahmer; Ramaswamy Govindan; Robert A Anders; Scott J Antonia; Sarah Sagorsky; Marianne J Davies; Steven M Dubinett; Andrea Ferris; Leena Gandhi; Edward B Garon; Matthew D Hellmann; Fred R Hirsch; Shakuntala Malik; Joel W Neal; Vassiliki A Papadimitrakopoulou; David L Rimm; Lawrence H Schwartz; Boris Sepesi; Beow Yong Yeap; Naiyer A Rizvi; Roy S Herbst
Journal:  J Immunother Cancer       Date:  2018-07-17       Impact factor: 13.751

10.  Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.

Authors:  J Ferlay; M Colombet; I Soerjomataram; C Mathers; D M Parkin; M Piñeros; A Znaor; F Bray
Journal:  Int J Cancer       Date:  2018-12-06       Impact factor: 7.396

View more
  10 in total

Review 1.  A narrative review on current imaging applications of artificial intelligence and radiomics in oncology: focus on the three most common cancers.

Authors:  Simone Vicini; Chandra Bortolotto; Marco Rengo; Daniela Ballerini; Davide Bellini; Iacopo Carbone; Lorenzo Preda; Andrea Laghi; Francesca Coppola; Lorenzo Faggioni
Journal:  Radiol Med       Date:  2022-06-30       Impact factor: 6.313

2.  Ability of Delta Radiomics to Predict a Complete Pathological Response in Patients with Loco-Regional Rectal Cancer Addressed to Neoadjuvant Chemo-Radiation and Surgery.

Authors:  Valerio Nardone; Alfonso Reginelli; Roberta Grassi; Giovanna Vacca; Giuliana Giacobbe; Antonio Angrisani; Alfredo Clemente; Ginevra Danti; Pierpaolo Correale; Salvatore Francesco Carbone; Luigi Pirtoli; Lorenzo Bianchi; Angelo Vanzulli; Cesare Guida; Roberto Grassi; Salvatore Cappabianca
Journal:  Cancers (Basel)       Date:  2022-06-18       Impact factor: 6.575

Review 3.  Radiomics in medical imaging: pitfalls and challenges in clinical management.

Authors:  Roberta Fusco; Vincenza Granata; Giulia Grazzini; Silvia Pradella; Alessandra Borgheresi; Alessandra Bruno; Pierpaolo Palumbo; Federico Bruno; Roberta Grassi; Andrea Giovagnoni; Roberto Grassi; Vittorio Miele; Antonio Barile
Journal:  Jpn J Radiol       Date:  2022-03-28       Impact factor: 2.701

4.  Pulmonary Lymphangitis Poses a Major Challenge for Radiologists in an Oncological Setting during the COVID-19 Pandemic.

Authors:  Roberta Fusco; Igino Simonetti; Stefania Ianniello; Alberta Villanacci; Francesca Grassi; Federica Dell'Aversana; Roberta Grassi; Diletta Cozzi; Eleonora Bicci; Pierpaolo Palumbo; Alessandra Borgheresi; Andrea Giovagnoni; Vittorio Miele; Antonio Barile; Vincenza Granata
Journal:  J Pers Med       Date:  2022-04-12

5.  Non-Invasive Measurement Using Deep Learning Algorithm Based on Multi-Source Features Fusion to Predict PD-L1 Expression and Survival in NSCLC.

Authors:  Chengdi Wang; Jiechao Ma; Jun Shao; Shu Zhang; Jingwei Li; Junpeng Yan; Zhehao Zhao; Congchen Bai; Yizhou Yu; Weimin Li
Journal:  Front Immunol       Date:  2022-04-07       Impact factor: 8.786

Review 6.  Multi-Omics Approaches for the Prediction of Clinical Endpoints after Immunotherapy in Non-Small Cell Lung Cancer: A Comprehensive Review.

Authors:  Vincent Bourbonne; Margaux Geier; Ulrike Schick; François Lucia
Journal:  Biomedicines       Date:  2022-05-26

Review 7.  Structured Reporting in Radiological Settings: Pitfalls and Perspectives.

Authors:  Vincenza Granata; Federica De Muzio; Carmen Cutolo; Federica Dell'Aversana; Francesca Grassi; Roberta Grassi; Igino Simonetti; Federico Bruno; Pierpaolo Palumbo; Giuditta Chiti; Ginevra Danti; Roberta Fusco
Journal:  J Pers Med       Date:  2022-08-21

Review 8.  A Narrative Review on LI-RADS Algorithm in Liver Tumors: Prospects and Pitfalls.

Authors:  Federica De Muzio; Francesca Grassi; Federica Dell'Aversana; Roberta Fusco; Ginevra Danti; Federica Flammia; Giuditta Chiti; Tommaso Valeri; Andrea Agostini; Pierpaolo Palumbo; Federico Bruno; Carmen Cutolo; Roberta Grassi; Igino Simonetti; Andrea Giovagnoni; Vittorio Miele; Antonio Barile; Vincenza Granata
Journal:  Diagnostics (Basel)       Date:  2022-07-07

Review 9.  What does radiomics do in PD-L1 blockade therapy of NSCLC patients?

Authors:  Ruichen Cui; Zhenyu Yang; Lunxu Liu
Journal:  Thorac Cancer       Date:  2022-08-29       Impact factor: 3.223

10.  Correlation between PD-L1 expression and radiomic features in early-stage lung adenocarcinomas manifesting as ground-glass nodules.

Authors:  Wenjia Shi; Zhen Yang; Minghui Zhu; Chenxi Zou; Jie Li; Zhixin Liang; Miaoyu Wang; Hang Yu; Bo Yang; Yulin Wang; Chunsun Li; Zirui Wang; Wei Zhao; Liang'an Chen
Journal:  Front Oncol       Date:  2022-09-13       Impact factor: 5.738

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.